AngiosarcomaSymptoms, Doctors, Treatments, Advances & More
Angiosarcoma Overview
Learn About Angiosarcoma
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Brigham And Women's Hospital, Division Of Surgical Oncology
Dr. Raut is the Chief of the Division of Surgical Oncology and the inaugural Distinguished Chair for Cancer Care at Brigham and Women's Hospital. He received a BA and BS from Stanford University, MSc from University of Oxford, and MD from Harvard Medical School, where he is also a Professor of Surgery. He completed his residency in general surgery at Massachusetts General Hospital and fellowship in surgical oncology at MD Anderson Cancer Center. Dr. Raut specializes in the multidisciplinary care of patients with soft tissue sarcoma and serves as the Surgery Director for the Center for Sarcoma and Bone Oncology at Dana-Farber Brigham Cancer Center (DFBCC). His research focuses on multimodal strategies to reduce rates of local recurrence for patients with sarcoma. Dr. Raut is rated as an Elite provider by MediFind in the treatment of Angiosarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Angiosarcoma, Nephrectomy, and Pancreaticoduodenectomy.
Advocate Lutheran General Cancer Institute
Pamela Kaiser is a Hematologist and an Oncologist in Park Ridge, Illinois. Dr. Kaiser is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. Her top areas of expertise are Angiosarcoma, Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and Endoscopy.
Advocate Christ Outpatient Pavilion Breast Surgery
Barbara Krueger is a General Surgeon in Oak Lawn, Illinois. Dr. Krueger is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, Inflammatory Breast Cancer, and Lymphadenectomy.
Summary: This is a single arm, open-label phase II study to assess the efficacy of single agent pembrolizumab for the treatment of advanced cutaneous sarcomas. Adult patients ≥18 years old who have been diagnosed with an advanced cutaneous sarcoma without regard to race, ethnicity, and/or gender. Approximately N=17 patients are planned to be enrolled. Pembrolizumab 200 mg will be administered as 30-minute ...
Summary: This is a multicenter, open-label study of Intratumoral Vusolimogene Oderparepvec (VO) to investigate safety and estimate when used in combination with pembrolizumab for treating participants with angiosarcoma. This is the first study evaluating this novel combination in participants with advanced angiosarcoma who have progressed after prior immunotherapy.


